Navigation Links
In First- and Second-Line Treatment of Clostridium Difficile Infection, Nearly 70 Percent of Surveyed Infectious Disease Specialists and Internists Will Use Fidaxomicin and Nearly Half Will Use CDA1/CDB1
Date:8/5/2010

WALTHAM, Mass., Aug. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in first- and second-line treatment of Clostridium difficile infection (CDI), nearly 70 percent of surveyed infectious disease specialists and internists will use Optimer's fidaxomicin and nearly half will use Medarex/Merck's CDA1 and CDB1, one year after the launch of these agents. The lower recurrent/relapse rate associated with fidaxomicin and CDA1/CDB1 is the most influential attribute surveyed clinicians cite in their decisions to prescribe these emerging agents for CDI.

The new Physician & Payer Forum report entitled Hospital Anti-Infectives: Insights on the Uptake and Formulary Inclusion of Emerging Antibiotics and Antifungals—A Survey of Infectious Disease Specialists, Internists and P&T Committee Members finds that fidaxomicin and, to a higher degree, CDA1/CDB1, will also see robust uptake by surveyed clinicians for the treatment of recurrent CDI. The report also finds that approximately two-thirds of pharmacy and therapeutics committee (P&T) members expect to include fidaxomicin and CDA1/CDB1 on their hospital's formulary.

Fidaxomicin and CDA1/CDB1 would provide much needed options for the treatment of CDI as the only currently available agents in this indication are Pfizer's metronidazole (generically available) and ViroPharma's Vancocin. According to the report, unmet need for novel anti-infectives is shifting away from methicillin-resistant Staphylococcus aureus (MRSA) to CDI and gram-negative infections.

"In addition to MRSA, infectious disease specialists report a rise in CDI and gram-negative infections," said Decision Resources Therapeutic Area Director Danielle Drayton, Ph.D. "Over the past 12 months, 82 percent of surveyed infectious disease specialists observed an increase in the incidence of ESBL-producing enterobacteriaceae while more than half of surveyed clinicians also point to an increase in the incidence of CDI and MRSA. Drugs that target key gram-negative pathogens such as Pseudomonas aeruginosa and ESBL-producing enterobacteriaceae and Clostridium difficile stand to address a key unmet need and will capitalize on untapped market opportunities."

The report also finds that Forest/AstraZeneca/Takeda's ceftaroline and Trius's torezolid are the two late-stage emerging therapies that are most likely to gain formulary inclusion, according to surveyed P&T committee members. Seventy one percent of surveyed P&T committee members expect torezolid to be on formulary and 62 percent expect ceftaroline to be on formulary.

Hospital Anti-Infectives: Insights on the Uptake and Formulary Inclusion of Emerging Antibiotics and Antifungals—A Survey of Infectious Disease Specialists, Internists and P&T Committee Members is based on a U.S. survey of 51 infectious disease specialists, 52 internal medicine specialists and 21 infectious disease specialists who sit on their hospital's P&T committee.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or

registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
2. WuXi PharmaTech Announces First-Quarter 2010 Results
3. WuXi PharmaTech Schedules First-Quarter 2010 Earnings Release
4. Ligon Discovery and Lycera Collaborate to Develop First-in-Class Drugs for Immune Disorders
5. Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
6. VELOCITY Broadcasting Introduces HD2PC(SM), the First-Ever High-Definition Direct to PC Delivery of Private Broadcast Television
7. JDRF Forms Partnership With Animas to Develop First-Generation Automated System for Managing Type 1 Diabetes
8. Mylan Confirms First-to-File Patent Challenge Relating to Vytorin(R) Cholesterol Medication
9. Lilly Declares First-Quarter 2010 Dividend
10. FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology
11. CPG Implements First-Ever Agile PLM Release 9.3 at Avema Pharma Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)...  Venice,s newest laser clinic, Physicians Advanced ... kind in the area and specializes in the ... The physician-owned and operated laser clinic is taking ... with its revitalizing skin care approach, unprecedented eVisit ... technology. http://photos.prnewswire.com/prnh/20160204/329957 --> ...
(Date:2/5/2016)... , Feb. 5, 2016  Henry Schein, Inc. (NASDAQ: ... care products and services to office-based dental, animal health ... into an agreement to acquire a majority ownership interest ... and equipment in Brazil . ... in Blumenau, Brazil, Dental Cremer is the dental distribution business ...
(Date:2/4/2016)... Feb. 4, 2016  Edwards Lifesciences Corporation (NYSE: ... structural heart disease and critical care monitoring, announced today ... (ASR) agreement with Morgan Stanley & Co. LLC to ... is part of the Company,s previously authorized program to ... stock.  --> --> ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure ... search for and donate to Give To Cure’s campaign that is crowdfunding clinical trials ... users make and share payments through a smart device. In 2015 alone, Venmo processed ...
(Date:2/5/2016)... ... February 05, 2016 , ... Pivot Point ... Best in KLAS: Software & Services for HIT Implementation Support & Staffing report ... independently ranks vendor performance by healthcare executives, managers and clinicians representing over 4,500 ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. Justin Scott and Dr. ... Annual No Cost Dental Day to individuals in need. The event is scheduled to ... No Cost Dental Day is to provide dental care to community members in need. ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. Ben Amini, a ... is now welcoming orthodontist, Dr. Amanda Cheng, to the practice. With the addition ... health care, including general dentistry, cosmetic treatments, periodontics, implant dentistry , endodontics, ...
(Date:2/5/2016)... ... February 05, 2016 , ... In sleep, when the ... a dream. A hallmark feature of patients with eating disorders is significant self-criticism, and ... disorder behaviors and obsessions are regarded as maladaptive means for coping with this unease, ...
Breaking Medicine News(10 mins):